Myasthenia Gravis Panel 1
Order Name
MYAS GRAV1
Test Number: 5551325
Revision Date 01/01/2024
Test Number: 5551325
Revision Date 01/01/2024
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
Acetylcholine Receptor Binding Antibody
|
See Test Notes | 11034-6 |
|
Striated Muscle Antibody Screen with Titer
|
Immunofluorescence Assay (IFA) | 5372-8 |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | 2 (1 mL) | Serum | Clot Activator SST | Refrigerated |
| Alternate 1 | 2 (1 mL) | Serum | Clot Activator (Red Top, No-Gel) | Refrigerated |
| Instructions | Separate serum from cells ASAP or within 2 hours of collection. Combined Stability for both tests: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) |
|||
| GENERAL INFORMATION | |
|---|---|
| Testing Schedule | Mon - Sat |
| Expected TAT | 4-5 Days |
| Clinical Use | Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. |
| Notes | See individual panel components for more information for those tests. |
| CPT Code(s) | 86041, 86255 |
| Lab Section | Reference Lab |